How Pfizer plans to turn around its R&D and win over investors
Since the start of 2020, companies developing Covid-19 vaccines have seen their stock prices double, triple, or, in one case, rise 40-fold. But not Pfizer, whose shares are flat on the year despite its stake in a coronavirus vaccine now in Phase 3.
As STAT’s Matthew Herper reports, the pharma giant has a plan to change that. Pfizer, which is soon to spin off its slower-growing businesses, is betting the future on a pipeline of novel therapies the company believes can change the standard of care and deliver returns in the process.
Pfizer is particularly bullish about its efforts in gene therapy, targeted cancer drugs, and medicines for autoimmune disease. In each case there’s plenty of competition. But Mikael Dolsten, the company’s chief scientific officer, believes Pfizer can succeed by “really taking the game to a new level, and integrating breakthrough technology with novel science.”
Read more.
As STAT’s Matthew Herper reports, the pharma giant has a plan to change that. Pfizer, which is soon to spin off its slower-growing businesses, is betting the future on a pipeline of novel therapies the company believes can change the standard of care and deliver returns in the process.
Pfizer is particularly bullish about its efforts in gene therapy, targeted cancer drugs, and medicines for autoimmune disease. In each case there’s plenty of competition. But Mikael Dolsten, the company’s chief scientific officer, believes Pfizer can succeed by “really taking the game to a new level, and integrating breakthrough technology with novel science.”
Read more.
No hay comentarios:
Publicar un comentario